Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 17;16(24):4209.
doi: 10.3390/cancers16244209.

Risk Factors for Venous Thromboembolism in Acute Promyelocytic Leukemia

Nikica Sabljic  1 , Nikola Pantic  1 , Marijana Virijevic  1   2 , Jovan Rajic  1 , Mirjana Cvetkovic  1 , Lazar Trajkovic  1 , Zlatko Pravdic  1 , Zoran Bukumiric  3 , Nada Suvajdzic Vukovic  1   2 , Andrija Bogdanovic  1   2 , Ana Vidovic  1   2 , Milena Todorovic Balint  1   2 , Jelena Bila  1   2 , Danijela Lekovic  1   2 , Irena Djunic  1   2 , Darko Antic  1   2 , Mirjana Mitrovic  1   2
Affiliations

Risk Factors for Venous Thromboembolism in Acute Promyelocytic Leukemia

Nikica Sabljic et al. Cancers (Basel). .

Abstract

Background: Acute promyelocytic leukemia (APL) is frequently associated with disseminated intravascular coagulation (DIC), leading to potentially life-threatening bleeding. Compared to bleeding, thromboses are a less commonly encountered problem.

Objective: The objective of our study was to identify the incidence and predictive value of demographic data, clinical-laboratory parameters, and thrombosis risk assessment models (RAMs) for venous thromboembolism (VTE) in patients with APL.

Methods: This study was a retrospective study conducted on adult patients with APL who were treated between 2006 and 2024 at the Clinic of Hematology UCCS with all-trans retinoic acid (ATRA) and anthracycline. The demographic and clinical-laboratory data related to VTE were collected and analyzed alongside the predictive value of two RAMs proposed by Al-Ani and Paterno and colleagues.

Results: Among the one-hundred-fifty-five adult patients with APL, VTE was diagnosed in twenty-eight cases (18.1%). The most common location for thrombosis was in the central venous catheter (CVC), which affected twelve (42.8%) patients. A total of six (21.4%) patients had deep vein thrombosis (DVT), one patient (3.6%) showed a pulmonary embolism (PE), and thrombosis at unusual sites was present in nine (32.1%) patients. Our analyses showed that neither Al-Ani's RAM nor the RAM proposed by Paterno and colleagues were predictive for VTE in patients with APL. The C statistics value for the Al-Ani model was ROC = 0.514, and, for Paterno's RAM, it was ROC = 0.521. The independent risk factors for VTE, identified via multivariate analysis, were CD114 expression (p = 0.005, OR = 6.4 IC 95%: [1.8-23.2]) and the absence of bleeding at presentation (p = 0.013, OR = 0.086 IC 95%: [0.01-0.59]).

Conclusions: To the best of our knowledge, this is the first study showing that a higher expression of CD114 increases the risk of VTE. The absence of bleeding at presentation in patients with APL correlates with thrombosis. Further analyses are needed to confirm these findings and help to develop therapeutic strategies to prevent VTE complications. So far, no risk assessment model has been sufficient to stratify patients with APL according to their risk of VTE.

Keywords: acute promyelocytic leukemia; risk assessment models; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Type of VTE and its occurrence during the course of disease.
Figure 2
Figure 2
Multivariate analyses of predictors for VTE in patients with APL.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. David S., Mathews V. Mechanisms and management of coagulopathy in acute promyelocytic leukemia. Thromb. Res. 2018;164((Suppl. S1)):S82–S88. doi: 10.1016/j.thromres.2018.01.041. - DOI - PubMed
    1. Hambley B.C., Tomuleasa C., Ghiaur G. Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care? Front. Med. 2021;8:722614. doi: 10.3389/fmed.2021.722614. - DOI - PMC - PubMed
    1. Gill H., Raghupathy R., Lee C.Y.Y., Yung Y., Chu H.T., Ni M.Y., Xiao X., Flores F.P., Yim R., Lee P., et al. Acute promyelocytic leukaemia: Population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. BMC Cancer. 2023;23:141. doi: 10.1186/s12885-023-10612-z. - DOI - PMC - PubMed
    1. Dally N., Hoffman R., Haddad N., Sarig G., Rowe J.M., Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. Thromb. Res. 2005;116:109–114. doi: 10.1016/j.thromres.2004.11.001. - DOI - PubMed
    1. De Stefano V., Sorà F., Rossi E., Chiusolo P., Laurenti L., Fianchi L., Zini G., Pagano L., Sica S., Leone G. The risk of thrombosis in patients with acute leukemia: Occurrence of thrombosis at diagnosis and during treatment. J. Thromb. Haemost. 2005;3:1985–1992. doi: 10.1111/j.1538-7836.2005.01467.x. - DOI - PubMed

LinkOut - more resources